{"entity":{"id":"richard-finn","kind":"person","name":"Richard S. Finn","aka":[],"tldr":"Led PALOMA-2, which made palbociclib a first-line breast cancer drug, and IMbrave150, which made immunotherapy the standard for liver cancer.","summary":"Richard Finn was principal investigator of PALOMA-2, the trial that established palbociclib plus letrozole as first-line therapy for HR-positive advanced breast cancer and launched the CDK4/6 inhibitor class. He then led IMbrave150, which showed atezolizumab plus bevacizumab beat sorafenib in unresectable hepatocellular carcinoma, ending a decade of sorafenib as the only option. His current work covers next-generation CDK inhibitors and immunotherapy sequencing in liver cancer.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Finn%20RS%5BAuthor%5D%20palbociclib%20OR%20atezolizumab"}],"tags":["breast","hcc","trialist"],"related":[],"cancers":["breast-hr-positive","hcc"],"sections":[],"technologies":["cdk46-inhibitor","checkpoint-inhibitor"],"targets":["cdk4-6","pdl1"],"drugs":["palbociclib","atezolizumab"],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":["paloma-2","imbrave150"],"people":[],"bottlenecks":[],"keyPapers":["paper-imbrave150-nejm-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine, UCLA Jonsson Comprehensive Cancer Center","institutionId":"ucla-jonsson","specialisms":["HR-positive breast cancer","CDK4/6 inhibitors","Hepatocellular carcinoma","Immunotherapy combinations"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Finn%20RS%5BAuthor%5D%20palbociclib%20OR%20atezolizumab"}],"papers":[{"title":"Palbociclib and letrozole in advanced breast cancer (PALOMA-2)","journal":"NEJM","year":2016,"doi":"10.1056/NEJMoa1607303"},{"title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma (IMbrave150)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa1915745"}]},"route":"/people/richard-finn/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/"}],"institution":[{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","route":"/institutions/ucla-jonsson/"}],"trial":[{"id":"imbrave150","kind":"trial","name":"IMbrave150","route":"/trials/imbrave150/"},{"id":"paloma-2","kind":"trial","name":"PALOMA-2","route":"/trials/paloma-2/"}],"paper":[{"id":"paper-imbrave150-nejm-2020","kind":"paper","name":"IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer","route":"/key-papers/paper-imbrave150-nejm-2020/"}]}}